NUCIEN PHARMA(SH:688189) 证券时报·2025-10-02 08:38Core Viewpoint - Nanjing Pharmaceutical (688189) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations in annual report disclosures, leading to the termination of its planned major asset restructuring [1][2][4]. Group 1: Investigation and Financial Performance - The company received a notice from the CSRC regarding the investigation due to alleged violations in annual report disclosures [2]. - In the first half of the year, Nanjing Pharmaceutical reported revenue of 61.8463 million yuan and a net loss of 40.0023 million yuan [3]. Group 2: Termination of Major Asset Restructuring - The planned major asset restructuring, which involved a cash acquisition of up to 480 million yuan for assets from Future Pharmaceutical, has been terminated due to a lack of consensus on core terms among the parties involved [4]. - The termination of the restructuring is stated to not adversely affect the company's business operations, financial status, or the interests of shareholders, particularly minority shareholders [4]. Group 3: Future Strategic Direction - The company plans to continue pursuing its strategic goals and seek development opportunities through investments, mergers, and collaborations to enhance its product matrix and improve profitability [5].